Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis, Inc. (NASDAQ: CRIS) reported its third-quarter 2020 financial results with a net loss of $6.0 million ($0.11 per share), an improvement from a loss of $6.4 million in Q3 2019. Total revenues were $2.7 million, slightly down from $2.9 million a year prior. Key operational highlights include ongoing Phase 1 studies for the IRAK4 inhibitor CA-4948 and the anti-VISTA antibody CI-8993. The company also secured a CRADA with NCI for CA-4948’s development and maintains a cash position of $23.6 million, sufficient for operations through mid-2021.
Curis, a biotechnology company (NASDAQ: CRIS), has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop CA-4948, an IRAK4 kinase inhibitor for cancer treatment. This collaboration aims to enhance CA-4948's clinical studies and validate Curis's approach to targeted cancer therapeutics. CA-4948 is currently in Phase 1 trials for non-Hodgkin lymphoma and acute myeloid leukemia. The company also plans a combination study with ibrutinib, expected to start in Q4 2020.
Curis, Inc. (NASDAQ: CRIS) announced the acceptance of three abstracts for CA-4948 presentations at the 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. CA-4948 is a first-in-class IRAK4 inhibitor aimed at treating various hematologic malignancies. Data from Phase 1 studies in non-Hodgkin's lymphoma and acute myeloid leukemia are expected by year-end. The company emphasizes progress and will share updated safety and efficacy results during the conference.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present at the H.C. Wainwright & Co. 6th Annual Israel Conference on November 12, 2020, at 12:00 pm ET. A live webcast will be available on Curis' website in the Investors section, with a replay accessible for 90 days post-event.
Curis is advancing multiple cancer treatments, including drugs in collaboration with Aurigene and Genentech. Their pipeline includes CA-4948 for non-Hodgkin lymphoma and acute myeloid leukemia, with ongoing Phase 1 clinical trials.
Curis, Inc. (NASDAQ: CRIS) will report its third quarter 2020 financial results on November 10, 2020, post market close. The management will conduct a conference call at 4:30 p.m. ET on the same day to discuss the results. The call can be accessed via phone or through the Curis website. Curis is known for developing innovative cancer therapeutics and has several key collaborations, including with Aurigene and Genentech for advanced treatment options and ongoing clinical trials.
Curis, Inc. (NASDAQ: CRIS) announced the publication of a research paper in ACS Medicinal Chemistry Letters, detailing CA-4948, an orally bioavailable IRAK4 inhibitor for treating hematologic malignancies. This small molecule demonstrated potent IRAK4 inhibition and showed tumor regression in animal studies without significant toxicity. CA-4948 is currently in Phase 1 trials for non-Hodgkin lymphomas and acute myeloid leukemia. Curis plans to commence a combination study with ibrutinib for non-Hodgkin lymphomas this quarter. Curis emphasizes the need for additional funding to support ongoing operations.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at two investor conferences on September 15, 2020. The first event is the Cantor Fitzgerald Virtual Global Healthcare Conference at 9:20 am ET, followed by the H.C. Wainwright & Co. 22nd Annual Global Investment Conference at 4:30 pm ET. Both presentations will be available via live webcast on the company's website, with replays accessible for 90 days post-event. Curis specializes in cancer therapeutics, with ongoing trials for several innovative drugs.
Curis, Inc. (NASDAQ: CRIS) reported its Q2 2020 financial results, highlighting a net loss of $6.7 million, or $0.17 per share, an improvement from a loss of $7.2 million in Q2 2019. Revenue increased to $2.4 million from $2.1 million year-over-year. The biotech firm advanced its clinical pipeline, notably the IRAK4 inhibitor CA-4948, with ongoing studies for non-Hodgkin's lymphoma and acute myeloid leukemia. FDA clearance was received for CI-8993, a new anti-VISTA antibody study. Curis expects cash to support operations through the first half of 2021.
Curis, Inc. (NASDAQ: CRIS) will announce its second quarter 2020 financial results on August 4, 2020, after US market close. A conference call is scheduled for the same day at 4:30 p.m. ET, accessible via phone or the company's website. Curis specializes in developing innovative therapeutics for cancer treatment and has ongoing collaborations focusing on immuno-oncology and precision oncology. The company holds exclusive licenses for several drug candidates currently in clinical trials.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
